MX388482B - Métodos para tratar el virus de la hepatitis c. - Google Patents

Métodos para tratar el virus de la hepatitis c.

Info

Publication number
MX388482B
MX388482B MX2016012799A MX2016012799A MX388482B MX 388482 B MX388482 B MX 388482B MX 2016012799 A MX2016012799 A MX 2016012799A MX 2016012799 A MX2016012799 A MX 2016012799A MX 388482 B MX388482 B MX 388482B
Authority
MX
Mexico
Prior art keywords
treatment
hepatitis
virus
treating
methods
Prior art date
Application number
MX2016012799A
Other languages
English (en)
Other versions
MX2016012799A (es
Inventor
Andrew L Campbell
Barry M Bernstein
Chih-Wei Lin
Rajeev M Menon
Sandeep Dutta
Thomas J Podsadecki
Tianli Wang
Walid M Awni
Wei Liu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52829479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX388482(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2016012799A publication Critical patent/MX2016012799A/es
Publication of MX388482B publication Critical patent/MX388482B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención caracteriza terapias libres de interferón para el tratamiento del VHC. Preferiblemente, el tratamiento es sobre una duración más corta de tratamiento, tal como no más de 12 semanas. En un aspecto, el tratamiento comprende administrar al menos dos agentes antivíricos de acción directa a un sujeto con la infección del VRC, en donde el tratamiento tiene una duración de 12 semanas y no incluye administración de ya sea interferón o ribavirina, y al menos los dos agentes antiviricos de acción directa comprenden (a) Compuesto 1 o una sal farmacéuticamente aceptable del mismo y (b) Compuesto 2 o una sal farmacéuticamente aceptable del mismo.
MX2016012799A 2014-04-02 2015-04-01 Métodos para tratar el virus de la hepatitis c. MX388482B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461973929P 2014-04-02 2014-04-02
US201461989951P 2014-05-07 2014-05-07
US201462016459P 2014-06-24 2014-06-24
PCT/US2015/023923 WO2015153793A1 (en) 2014-04-02 2015-04-01 Methods for treating hcv

Publications (2)

Publication Number Publication Date
MX2016012799A MX2016012799A (es) 2016-12-12
MX388482B true MX388482B (es) 2025-03-20

Family

ID=52829479

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012799A MX388482B (es) 2014-04-02 2015-04-01 Métodos para tratar el virus de la hepatitis c.

Country Status (9)

Country Link
US (2) US10286029B2 (es)
EP (1) EP3125889A1 (es)
JP (2) JP6632992B2 (es)
CN (4) CN112704726A (es)
AU (3) AU2015240754B2 (es)
BR (1) BR112016022976A8 (es)
CA (1) CA2942823C (es)
MX (1) MX388482B (es)
WO (1) WO2015153793A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20200368229A9 (en) * 2013-03-14 2020-11-26 Abbvie Inc. Methods for Treating HCV
US20180042982A1 (en) * 2013-03-14 2018-02-15 Abbvie Inc. Methods for Treating HCV
CN112704726A (zh) * 2014-04-02 2021-04-27 艾伯维公司 治疗hcv的方法
EP3125890A1 (en) * 2014-04-02 2017-02-08 AbbVie Inc. Methods for treating hcv
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
US20180177779A1 (en) * 2015-07-08 2018-06-28 Abbvie Inc. Methods for Treating HCV
EP3515442A4 (en) * 2016-09-23 2020-05-06 AbbVie Inc. ADJUSTMENT
JP2018131439A (ja) * 2017-02-14 2018-08-23 アッヴィ・インコーポレイテッド Ｈｃｖを処置する方法
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
EP3883569A1 (en) * 2018-11-20 2021-09-29 Abbvie Inc. Methods for treating acute hcv
JP6734610B1 (ja) 2020-03-31 2020-08-05 株式会社ビードットメディカル 超電導電磁石装置及び荷電粒子ビーム照射装置
JP6807125B1 (ja) 2020-06-17 2021-01-06 株式会社ビードットメディカル 荷電粒子ビーム照射装置

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3680106A (en) 1963-05-07 1972-07-25 Us Navy Method for displaying the range detection capability of a search radar in a noisy environment
US3466159A (en) 1965-03-26 1969-09-09 Chemical Construction Corp Process and catalyst for production of methane-rich gas
US3492386A (en) 1967-06-06 1970-01-27 Okura Industrial Co Ltd Extending process and device for tubular films of thermoplastic synthetic resin
US3685984A (en) 1970-09-04 1972-08-22 Dow Chemical Co Removing metal carbides from furnace systems
US3648037A (en) 1970-12-31 1972-03-07 Gen Electric Symmetrical function generator
BE791313A (fr) 1971-12-13 1973-05-14 Baker Perkins Inc Appareillage de demoulage, notamment pour produits de boulangerie
US3853176A (en) 1973-03-01 1974-12-10 Bergeson Caswell Inc Well cleaning apparatus
FR2260465B1 (es) 1974-02-07 1977-05-20 Siemens Ag
US20040018237A1 (en) 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
AU2003900553A0 (en) 2003-02-10 2003-02-20 Borody, Thomas Julius Novel Improved Method for Detection of Dientamoeba fragilis and other Parasites
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
BR112013006693B1 (pt) * 2010-09-21 2022-07-12 Enanta Pharmaceuticals, Inc Compostos inibidores da serino protease hcv derivada de prolina macrocíclica
CN105381450A (zh) * 2010-11-30 2016-03-09 诺华有限公司 丙型肝炎病毒感染的新疗法
CN105749246A (zh) * 2011-03-31 2016-07-13 诺华股份有限公司 治疗丙肝病毒感染的阿拉泊韦
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9079887B2 (en) * 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
JP2015528512A (ja) 2012-09-18 2015-09-28 アッヴィ・インコーポレイテッド Ｃ型肝炎を治療するための方法
AU2013318302B2 (en) 2012-09-18 2018-02-22 Abbvie Inc. Methods for treating hepatitis C
WO2014099908A1 (en) 2012-12-17 2014-06-26 Genentech, Inc. Methods for inhibiting viral infection in transplant patients
NZ719137A (en) 2013-03-14 2017-11-24 Abbvie Inc Combination of two antivirals for treating hepatitis c
CA2925328A1 (en) 2013-10-25 2015-04-30 Abbvie, Inc. Methods for treating hcv
EP3125890A1 (en) 2014-04-02 2017-02-08 AbbVie Inc. Methods for treating hcv
CN112704726A (zh) 2014-04-02 2021-04-27 艾伯维公司 治疗hcv的方法
US20180177779A1 (en) 2015-07-08 2018-06-28 Abbvie Inc. Methods for Treating HCV

Also Published As

Publication number Publication date
CN106413711A (zh) 2017-02-15
US10286029B2 (en) 2019-05-14
AU2015240754B2 (en) 2020-06-25
US20160317602A9 (en) 2016-11-03
AU2015240754A1 (en) 2016-09-29
US20190336565A1 (en) 2019-11-07
MX2016012799A (es) 2016-12-12
BR112016022976A8 (pt) 2021-07-20
AU2022209336A1 (en) 2022-08-25
JP6632992B2 (ja) 2020-01-22
CN112891511A (zh) 2021-06-04
JP2017509670A (ja) 2017-04-06
JP2020063275A (ja) 2020-04-23
CA2942823A1 (en) 2015-10-08
CN112704726A (zh) 2021-04-27
WO2015153793A1 (en) 2015-10-08
EP3125889A1 (en) 2017-02-08
US20150283198A1 (en) 2015-10-08
BR112016022976A2 (pt) 2017-08-15
CA2942823C (en) 2023-01-03
AU2020239800A1 (en) 2020-10-29
CN110302361A (zh) 2019-10-08

Similar Documents

Publication Publication Date Title
MX388482B (es) Métodos para tratar el virus de la hepatitis c.
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
CL2018002549A1 (es) Eliminación del virus de la hepatitis b con agentes antivirales
PH12018550201A1 (en) Hepatitis b antiviral agents
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
MX384836B (es) Agentes antivirales contra la hepatitis b
MX389088B (es) Métodos para tratar el vhc.
RU2015114543A (ru) Способы лечения гепатита с
MX2015017953A (es) Metodos para tratar el virus de hepatitis c.
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
EA201692514A1 (ru) Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением
MX2020001422A (es) Metodos para el tratamiento de hcv.
MX2018001905A (es) Metodos para el tratamiento del virus de hepatitis c (vhc).
MX2018000213A (es) Metodos para tratar el vhc.
EA201692515A1 (ru) Новая фармацевтическая композиция на основе софосбувира и рибавирина
AU2019384793A8 (en) Methods for treating acute HCV
NZ631789A (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients
EA201892004A1 (ru) Противовирусные средства для лечения гепатита b
EA202092602A2 (ru) -d-2'-дезокси-2'--фтор-2'--c-замещенные-2-модифицированные-n6-замещенные пуриновые нуклеотиды для лечения вызванных hcv заболеваний
EA201892732A1 (ru) Противовирусные средства для лечения гепатита в